In a re-analysis of a randomized, placebo-controlled trial, the GLP-1 drug semaglutide slowed multiple DNA-methylation “epigenetic clocks” by roughly two to five years per year over eight months in people with HIV-associated fat accumulation. The signal is consistent across the clocks most tied to mortality risk, but the study was exploratory, small, and not designed to test aging.
Semaglutide — the molecule behind Ozempic and Wegovy — has already rewritten the playbook on obesity and cardiovascular risk. Now a team led by researchers at the University of California San Diego and University Hospitals Cleveland Medical Center reports that the same once-weekly injection may also nudge the body’s biological clock backward.
The “big idea” here is geroscience repurposing: taking a drug already approved for a metabolic condition and asking whether it acts on aging itself, rather than just one disease. To test this, the team did not run a new trial. They reached into the biobank of a completed 32-week phase 2b study in people living with HIV who had lipohypertrophy — a stubborn accumulation of visceral and ectopic fat that accelerates aging. From frozen blood cells collected before and after treatment, they read DNA methylation, the chemical marks that act like an aging dashboard, and ran the data through 17 different epigenetic clocks spanning three generations of the technology.
The pattern was strikingly consistent. Across the clocks built to predict disease and death — PhenoAge, GrimAge, OMICmAge, and the rate-of-aging measure DunedinPACE — the semaglutide group aged more slowly than placebo, while the placebo group’s clocks ticked upward as expected. PhenoAge showed the largest shift, an adjusted difference of nearly five years of biological aging avoided per calendar year. DunedinPACE indicated roughly a 9 percent slower pace of aging. A panel of organ-specific clocks suggested the strongest effects in inflammation, brain, heart, and liver aging — fitting semaglutide’s known multi-organ reach.
Why might a weight-loss drug touch the aging clock at all? The leading hypothesis is that semaglutide strips away visceral fat and dampens the chronic, low-grade inflammation that drives accelerated aging — partially erasing an “obesogenic epigenetic memory” embedded in fat tissue.
The caveats are substantial and the authors are upfront about them. This was a post hoc analysis, never designed or powered to study aging, in a specialized HIV cohort of 84 people followed for only eight months. Epigenetic clocks are correlations, not proof of a longer life. Still, as the first randomized-trial evidence that a licensed GLP-1 drug can move validated aging biomarkers, it is a meaningful flag planted for the prospective trials that must come next.
Actionable Insights
The honest take-home: this is hypothesis-generating, not a protocol. The cohort was people with HIV and visceral fat, not healthy adultsl. That said, the direction of the findings reinforces several well-established levers, and the effect sizes are worth quantifying.
The magnitude is real but modest. The headline PhenoAge effect of −4.9 years/year is an annualized projection from an eight-month window; in absolute terms over the actual 32 weeks, the semaglutide group avoided roughly 3 years of PhenoAge acceleration relative to placebo. DunedinPACE moved about 0.09 units, a ~9 percent slower aging pace. Translated to standardized effect sizes (Cohen’s d, back-calculated from the reported confidence intervals), the benefits sit in the medium range: roughly d ≈ 0.6 for PhenoAge and PCGrimAge, d ≈ 0.5 for DunedinPACE and OMICmAge. These are not the trivial effects often dressed up by small p-values, but they are also not transformative.
The actionable through-line is that visceral fat loss and inflammation reduction track with younger epigenetic clocks. Whether achieved by a GLP-1 drug, caloric restriction (echoing the CALERIE trial), or a multimodal lifestyle program (echoing DO-HEALTH), reducing central adiposity and systemic inflammation appears to be the shared mechanism. For most readers the validated levers remain weight management, metabolic health, and lowering hsCRP — semaglutide is one pharmacological route, not a unique key.
Source:
- Open Access Paper: Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertroph
- Institutions: University of California San Diego (lead); University Hospitals Cleveland Medical Center; Case Western Reserve University; Medical University of South Carolina; TruDiagnostic (Lexington, Kentucky — commercial epigenetics lab and clock provider).
- Country: United States.
-
Journal: Nature Communications (Springer Nature).
Impact Evaluation: The impact score of this journal is 15.7 (JIF), evaluated against a typical high-end range of 0–60+ for top general-science journals, therefore this is a High impact journal. (Note: it sits well below the elite tier occupied by Nature, Science, and Cell at JIF ~45–65, but is a leading, highly selective multidisciplinary venue.)
Related reading:
- Amount of Central Fat Predicts Mortality Risk in Non-Obese Individuals
- The Skinny-Fat Paradox: Why a "Normal" BMI Leaves Millions of Women Critically Vulnerable to Metabolic Disease
- Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife (paper March 26)